Dyax Corp. To Webcast 2015 Research And Development Day
Company to Review Third Quarter 2015 Financial Results as Part of R&D Day
BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) will host a Research and Development (R&D) Day for institutional investors and research analysts on Monday, November 2, 2015 from 8:00 a.m. to 1:30 pm ET in New York City.
The R&D related agenda includes presentations on DX-2930 for the prevention of hereditary angioedema (HAE) attacks, DX-2930 for diabetic macular edema, DX-2507 (anti-FcRn), DX-4012 (anti-Factor XIIa), and other earlier stage product candidates. The Company will also discuss its regulatory and manufacturing strategy.
As previously announced, third quarter 2015 financial results will be released on Wednesday, October 28, 2015 after market close. However, in lieu of the previously announced conference call and webcast of these financial results, the Company will review financial results at the beginning of the R&D Day.
The event will be webcast live and can be accessed under the Investor Relations section of the Company's website at http://investor.dyax.com/events.cfm. Due to space limitations, on-site attendance is limited to invited guests. A replay of the webcast will be available on the Dyax website.
Dyax is a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs. The Company is developing DX-2930, an investigational fully human monoclonal antibody, for the prevention of HAE attacks. Dyax plans to initiate a single, pivotal Phase 3 clinical trial evaluating DX-2930 in HAE by year-end 2015. Additionally, Dyax markets KALBITOR® (ecallantide) for the treatment of acute attacks of HAE in patients 12 years of age and older.
Both DX-2930 and KALBITOR were identified using Dyax's proprietary phage display technology. Dyax has broadly licensed this technology under its Licensing and Funded Research Portfolio (LFRP). The current portfolio includes one FDA approved product, Eli Lilly and Company’s CYRAMZA® (ramucirumab), for which Dyax receives royalties, and multiple product candidates in various stages of clinical development for which the Company is eligible to receive future milestones and royalties.
For additional information about Dyax, please visit www.dyax.com.
For additional information about KALBITOR, including full prescribing information, please visit www.KALBITOR.com.
This press release contains forward-looking statements. Statements that are not historical facts are based on Dyax's current expectations, beliefs, assumptions, estimates, forecasts and projections about the industry and markets in which Dyax operates. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements because of risks, uncertainties and assumptions involved in any future projections. There are many factors that could cause actual results to differ from these forward-looking statements, including: risks and uncertainties relating to the clinical development, regulatory approval and commercial manufacturing of DX-2930 and other product candidates; Dyax's dependence on the expertise, effort, priorities and contractual obligations of third parties in the development of DX-2930 and other product candidates and in the marketing, sales and distribution of KALBITOR; competition from new and existing treatments for HAE; the uncertainty of patent and intellectual property protection relating to DX-2930 and other product candidates, KALBITOR and the LFRP; Dyax's dependence on licensees and collaborators for development, clinical trials, manufacturing, sales and distribution of product candidates in the LFRP; uncertainties as to whether one or more product candidates in the LFRP will progress in clinical development, receive commercial approval, and generate royalties; milestone payments under our LFRP may be delayed, withheld, or challenged by our licensees; and other risk factors described or referred to in Item 1A, "Risk Factors" in Dyax's most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Dyax cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Dyax undertakes no obligations to update or revise these statements, except as may be required by law.
Dyax, the Dyax logo and KALBITOR are registered trademarks of Dyax Corp.
CYRAMZA is a trademark owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates.
Jennifer Robinson, 617-250-5741
Director, Investor Relations and Corporate Communications